Humana Inc. $HUM Stock Sold by Generali Asset Management SPA SGR

Key Points

• Generali Asset Management cut its Humana stake by 50.6% in the third quarter, selling 19,267 shares and retaining 18,842 shares valued at approximately $7.19 million. Institutional investors and hedge funds collectively own 92.38% of Humana.
• Analyst sentiment remains positive, with Humana carrying a “Moderate Buy” consensus rating and an average price target of $453.30, above its reported opening price of $411.36.
• Humana exceeded quarterly expectations with earnings of $7.61 per share and revenue of $40.89 billion, while declaring a quarterly dividend of $0.885 per share, equivalent to a 0.9% annualized yield.

Generali Asset Management SPA SGR lessened its position in shares of Humana Inc. (NYSE:HUM - Free Report) by 50.6% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 18,842 shares of the insurance provider's stock after selling 19,267 shares during the quarter. Generali Asset Management SPA SGR's holdings in Humana were worth $7,190,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the company. BlackRock Inc. acquired a new stake in shares of Humana during the second quarter worth about $4,138,160,000. Pzena Investment Management LLC boosted its position in Humana by 34.3% in the first quarter. Pzena Investment Management LLC now owns 5,470,982 shares of the insurance provider's stock valued at $948,614,000 after buying an additional 1,398,774 shares during the last quarter. Assenagon Asset Management S.A. boosted its position in Humana by 20,126.8% in the third quarter. Assenagon Asset Management S.A. now owns 1,255,479 shares of the insurance provider's stock valued at $479,053,000 after buying an additional 1,249,272 shares during the last quarter. Legal & General Group Plc acquired a new position in Humana in the 2nd quarter worth approximately $329,760,000. Finally, Barrow Hanley Mewhinney & Strauss LLC acquired a new position in Humana in the 2nd quarter worth approximately $314,922,000. 92.38% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on HUM shares. Raymond James Financial raised shares of Humana from a "market perform" rating to an "outperform" rating and set a $520.00 price target for the company in a research report on Monday, October 12th. UBS Group upped their price objective on shares of Humana from $405.00 to $495.00 and gave the company a "neutral" rating in a report on Monday, October 12th. Wolfe Research reaffirmed an "outperform" rating and issued a $450.00 price objective on shares of Humana in a report on Monday, August 24th. Zacks Research lowered shares of Humana from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 11th. Finally, Piper Sandler raised shares of Humana from a "hold" rating to an "overweight" rating and set a $463.00 target price for the company in a report on Thursday, July 30th. Twenty-one analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, Humana presently has an average rating of "Moderate Buy" and an average target price of $453.30.

Humana Trading Down 0.8%

HUM stock opened at $411.36 on Thursday. Humana Inc. has a 12-month low of $163.11 and a 12-month high of $456.50. The business's 50-day moving average is $399.48 and its 200 day moving average is $307.32. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.62. The stock has a market cap of $49.40 billion, a price-to-earnings ratio of 38.92, a PEG ratio of 2.60 and a beta of 0.74.

Humana (NYSE:HUM - Get Free Report) last announced its earnings results on Wednesday, July 29th. The insurance provider reported $7.61 EPS for the quarter, beating analysts' consensus estimates of $7.27 by $0.34. Humana had a return on equity of 11.20% and a net margin of 0.88%. The business had revenue of $40.89 billion during the quarter, compared to analysts' expectations of $40.58 billion. During the same quarter in the prior year, the firm earned $6.27 earnings per share. The business's revenue was up 26.2% compared to the same quarter last year. On average, sell-side analysts anticipate that Humana Inc. will post 9.03 EPS for the current fiscal year.

Humana Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, November 27th. Stockholders of record on Friday, October 30th will be given a $0.8850 dividend. The ex-dividend date is Friday, October 30th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 0.9%. Humana's dividend payout ratio is 33.49%.

Humana Company Profile

Humana Inc is a health and well-being company that provides insurance products and health care services in the United States and Puerto Rico. The company's primary business is government-sponsored health coverage, particularly Medicare Advantage plans for older adults, along with Medicare prescription drug plans, Medicaid coverage and certain commercial health insurance products.

Humana also operates CenterWell, its health care services platform focused on older adults. CenterWell includes primary care clinics, home health services and pharmacy services, with an emphasis on coordinated care, chronic-condition management and helping members receive care in lower-cost settings.

Founded in 1961 as a nursing-home company, Humana expanded into hospital operations before shifting its focus toward health insurance and related services.

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.